New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
09:03 EDTOREXBlue Chip says Orexigen accelerating patient enrollment for The Light Study
Blue Chip Patient Recruitment, a division of Blue Chip Marketing Worldwide, said it has partnered with Orexigen Therapeutics to accelerate patient enrollment of The Light Study, Orexigenís cardiovascular outcomes trial evaluating Contrave, an investigational medication being evaluated for the treatment of obesity. Approximately 9,000 patients will be randomized in the study within the next few weeks, nearly 14 months ahead of original forecasts, Blue Chip said.
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
08:08 EDTOREXOrexigen and Takeda announce availability of Contrave tablets for patients
Takeda Pharmaceutical, its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A. and Orexigen Therapeutics jointly announced that Contrave extended-release tablets are now available to patients by prescription in pharmacies across the U.S.. Contrave is approved by the FDA as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater, or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition.
October 15, 2014
08:35 EDTOREXOrexigen earned $60M milestone payment from Takeda Pharmaceutical
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use